Literature DB >> 22436613

Hepatocyte growth factor activates Wnt pathway by transcriptional activation of LEF1 to facilitate tumor invasion.

Fang-I Huang1, Yu-Ling Chen, Chih-Ning Chang, Ray-Hwang Yuan, Yung-Ming Jeng.   

Abstract

Hepatocyte growth factor (HGF) is a secretory protein that plays important roles in cancer growth and metastasis. Lymphoid-enhancing factor 1 (LEF1) is a transcription factor mediating Wnt/β-catenin signaling. Using microarray analysis, we found HGF induced expression of LEF1 in liver and breast cancer cell lines. HGF induced expression of LEF1 through phosphatidylinositol 3-kinase/Akt and nuclear factor-kappa B (NF-κB) signaling. Multiple NF-κB-binding sites were mapped within 3 kb upstream of LEF1 transcription initiation site. NF-κB binding to a site 2 kb upstream of LEF1 transcription initiation site was confirmed by chromatin immunoprecipitation assay. Knockdown of LEF1 inhibited the expression of Slug and Zinc finger E-box-binding homeobox 2 (ZEB2) and markedly attenuated HGF-induced tumor migration and invasion. Using immunohistochemical staining, we found LEF1 was frequently expressed in multiple types of carcinoma but not in the non-tumorous epithelial cells. Our finding suggest that transcriptional activation of LEF1 is a mechanism of cross talk between HGF/c-Met and Wnt/β-catenin pathways and is essential for HGF-induced tumor invasion.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22436613     DOI: 10.1093/carcin/bgs131

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  23 in total

1.  Overexpression of lymphoid enhancer-binding factor 1 (LEF1) in solid-pseudopapillary neoplasms of the pancreas.

Authors:  Aatur D Singhi; Mhammed Lilo; Ralph H Hruban; Kristi L Cressman; Kimberly Fuhrer; Raja R Seethala
Journal:  Mod Pathol       Date:  2014-03-21       Impact factor: 7.842

2.  Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion.

Authors:  Mireia Náger; Maria Santacana; Deepshikha Bhardwaj; Joan Valls; Isidre Ferrer; Pere Nogués; Carles Cantí; Judit Herreros
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  Constructing a novel prognostic signature of tumor driver genes for breast cancer.

Authors:  Liqiang Zhou; Yali Yi; Chuan Liu; Zhiqing Chen
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

4.  Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells.

Authors:  Kang Ho Kim; Ho Jun Seol; Eun Hee Kim; Jinguen Rheey; Hyun Jin Jin; Yeri Lee; Kyeung Min Joo; Jeongwu Lee; Do-Hyun Nam
Journal:  Neuro Oncol       Date:  2012-12-20       Impact factor: 12.300

5.  Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group.

Authors:  G Pentheroudakis; E A Kotteas; V Kotoula; K Papadopoulou; E Charalambous; A Cervantes; T Ciuleanu; G Fountzilas; N Pavlidis
Journal:  Clin Exp Metastasis       Date:  2014-07-05       Impact factor: 5.150

Review 6.  Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment.

Authors:  Larion Santiago; Garrett Daniels; Dongwen Wang; Fang-Ming Deng; Peng Lee
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

7.  MiR-145 regulates epithelial to mesenchymal transition of breast cancer cells by targeting Oct4.

Authors:  Jiajia Hu; Hua Guo; Hongyan Li; Yan Liu; Jingjing Liu; Liwei Chen; Jin Zhang; Ning Zhang
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

8.  Rhesus monkey model of liver disease reflecting clinical disease progression and hepatic gene expression analysis.

Authors:  Hong Wang; Tao Tan; Junfeng Wang; Yuyu Niu; Yaping Yan; Xiangyu Guo; Yu Kang; Yanchao Duan; Shaohui Chang; Jianpeng Liao; Chenyang Si; Weizhi Ji; Wei Si
Journal:  Sci Rep       Date:  2015-10-07       Impact factor: 4.379

9.  IGF2BP1 promotes mesenchymal cell properties and migration of tumor-derived cells by enhancing the expression of LEF1 and SNAI2 (SLUG).

Authors:  Anne Zirkel; Marcell Lederer; Nadine Stöhr; Nikolaos Pazaitis; Stefan Hüttelmaier
Journal:  Nucleic Acids Res       Date:  2013-05-15       Impact factor: 16.971

10.  Knockdown of lymphoid enhancer factor 1 inhibits colon cancer progression in vitro and in vivo.

Authors:  Wen-Juan Wang; Yu Yao; Li-Li Jiang; Ting-Hua Hu; Jie-Qun Ma; Zi-Jun Liao; Jun-Tao Yao; Dong-Fan Li; Shu-Hong Wang; Ke-Jun Nan
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.